Ambrx Biopharma Price to Book Ratio 2020-2022 | AMAM

Historical price to book ratio values for Ambrx Biopharma (AMAM) over the last 10 years. The current price to book ratio for Ambrx Biopharma as of January 25, 2023 is 0.59.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Ambrx Biopharma Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2023-01-26 1.90 inf
2021-06-30 19.60 0.00
2021-12-31 9.03 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.083B $0.007B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.571B 9.49
GSK (GSK) United Kingdom $71.996B 8.97
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.433B 19.52
Ginkgo Bioworks Holdings (DNA) United States $3.414B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.676B 25.16
Biohaven (BHVN) United States $1.305B 0.00
Emergent Biosolutions (EBS) United States $0.671B 5.28
ADC Therapeutics SA (ADCT) Switzerland $0.359B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00